Global Community

A 114-year-old piston-ring company just became one of the sexiest names in AI infrastructure. Here's the whole seduction — and the cold shower that followed.Read more

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Workday’s business signals look stronger even as the stock keeps sliding, with customers committing to future use and more companies turning on its built-in AI tools instead of walking away. See what that could mean for future sales and profits—and what signs would show the worry about AI replacing Workday is starting to come true.Read more

Lincoln, a very small market cap Mining explorer with lots of potential. Lincoln Minerals (ASX: LML) is an Australian exploration and development company focused on critical minerals projects in South Australia’s Gawler Craton / Eyre Peninsula region.Read more

Oscar Health looks wildly underappreciated compared with what its business could be worth, even after baking in cautious expectations. The story hinges on fast growth, strong cash generation, and a sturdy balance sheet—along with a few key assumptions that could quickly change the picture if they slip.Read more

Southern Silver is betting on the price of silver rising, aiming to sell or partner its big Mexican mine project when the market turns. With a management team that has sold a similar project before and heavy insider ownership, the upside could be large—but it depends on metal prices and patience.Read more

🪥Business Overview Key Metrics Total: 9.5/17 +2 ✅ Projected Operating Margin: 21.00% +0 ⚠️ Projected 5-Year Revenue CAGR: 3.00% +1 ✅ Last 5-Year ROIC: 16.84% +1 ✅ Estimated Cost of Capital: 8.32% (less than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.88% -1 ❌ Projected 5-Year EPS CAGR: 2.56% (given the ease of manipulating earnings metrics, sub-10% growth warrants caution) +0 ⚠️ Projected 5-Year Dividend CAGR: 4.69% +1.5 ✅ Moody's Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide +2 ✅✅ Morningstar Uncertainty: Low Procter & Gamble operates within a very competitive environment. However, its higher operating margins and wide moat its a clear sign it still operates with competitive advantages over its competitors as well as it has the capability of raising prices if needed.Read more

In a nutshell: Hims & Hers has invested heavily and benefits are starting to show through growth and expansion. Investing continues with steps taken with a clear long term goal on the background, to be a front door for customers, the delivery channel, the platform and ecosystem.Read more

A company that looks wildly cheap on paper may be flashing a danger sign, with reports in German media alleging unpaid obligations, pulled bank support, and legal threats toward critics. If you’re tempted by the glossy numbers, this is a reminder to ask whether the story holds up before you commit money.Read more